Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in women with HR+ / HER2- metastatic breast cancer and non-visceral disease
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary) ; Xentuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms XENERA-1
- Sponsors Boehringer Ingelheim
- 16 Sep 2019 Planned End Date changed from 8 Jul 2022 to 3 Nov 2022.
- 16 Sep 2019 Planned primary completion date changed from 3 May 2021 to 25 Aug 2021.
- 09 Jul 2019 Planned End Date changed from 12 Jan 2022 to 8 Jul 2022.